spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Turkish Cargo adds Kuala Lumpur and Ahmedabad to its cargo flight network.

Turkish Cargo


 
The new addition to the flight network of the flag carrier’s air cargo brand, Kuala Lumpur is both cultural and financial capital of Malaysia, boasting a considerable import and export potential. The aim here is to carry electronic products, medical products, and spare parts to all various countries around the world and especially Frankfurt and Amsterdam in Europe and Chicago, Atlanta, and Houston in the United States.

Turkish Cargo plans to perform its Kuala Lumpur flights, which will be operated with Boeing 777F cargo aircraft, on the ISL–KUL–SGN (Ho Chi Minh/Vietnam) route, thus creating a strong import-export line in the region.

Located in western India, Ahmedabad is the biggest city of the State of Gujarat and it has been connected with Doha and Bahrain destinations that possess high import potential. One of the fastest growing cities, Ahmedabad is a considerable pharmaceuticals market.

A holder of IATA CEIV Pharma certificate, which is the global quality standard for pharmaceutical transportation and operating as per the relevant competency criteria, Turkish Cargo aims to become an important air cargo brand for Ahmedabad. The flights will be on the DOH–AMD–ISL and BAH–AMD-ISL routes and they will be operated with Airbus 330F cargo aircraft.

Covering the world with its wide flight network that spans over 300 destinations in 126 countries, Turkish Cargo continues to be the preferred in air cargo transportation by ensuring a sustainable growth with its infrastructure, operational capabilities, fleet, and specialist teams.

To view the flight schedules and details please visit www.turkishcargo.com.tr, or contact with the call center at +90 850 333 0 777.
 


phone +90 212 463 63 63
web www.turkishcargo.com.tr/en
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Signant Health Joins the Association of Clinical Research Organizations (ACRO) to Add a Technology Perspective to Conversations with Legislators and Industry Leaders about the Future of Clinical Research

PHILADELPHIA, PA – November 21, 2019: Signant Health announced today that it has joined the non-profit Association of Clinical Research Organizations (ACRO). ACRO, a global coalition of research and technology companies, makes it their mission to advocate as the collective voice of the innovative clinical research industry to regulators and policymakers, educating stakeholders and shaping policies that foster efficient, effective and safe conduct of clinical research.
More info >>


White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement